The OFT has found that Reckitt Benckiser abused its dominant position in
the market for the NHS supply of alginate and antacid heartburn
medicines, in breach of the Chapter II prohibition of the Competition
Act 1998 and Article 102 of the Treaty on the Functioning of the
European Union. The OFT found that Reckitt Benckiser abused its dominant
position by withdrawing and de-listing Gaviscon Original Liquid from the
NHS prescription channel in 2005.
Summary of work
In November 2008, the OFT opened a formal investigation into allegations
that Reckitt Benckiser had abused a dominant position. These allegations
were brought to the OFT's attention by a report on BBC Newsnight
On 23 February 2010 the OFT issued a Statement of Objections alleging
that Reckitt Benckiser abused its dominant position in the market for
the NHS supply of alginate and antacid heartburn medicines.
On 15 October 2010 the OFT announced that it had reached an early
resolution agreement with Reckitt Benckiser, which had admitted
infringing UK and European competition law and agreed to pay a penalty
of £10.2 million.
On 13 April 2011, the OFT announced its decision, imposing a penalty of
£10.2 million on Reckitt Benckiser.